Beard Bros and BRITISH CANNABIS™ have announced a commercial collaboration focused on developing and expanding cannabinoid products across the United Kingdom, Europe and North America.
The collaboration connects two companies shaped by different regulated cannabis markets and united by a shared interest in responsible product development, consumer education and international growth. BRITISH CANNABIS™ brings UK-based manufacturing, formulation and regulatory experience across consumer cannabinoid products and prescription medicines. Beard Bros contributes more than a decade of legal cannabis experience, an established product identity, direct relationships across the American cannabis industry and a media platform built to inform consumers and operators.
Planned product categories include CBD tinctures, CBD gummies and CBG formulations developed for eligible markets. Transdermal patches and cannabinoid vapes may join the range in the future, subject to product development, market suitability and applicable regulatory requirements.
The commercial collaboration will support market-specific products developed for the requirements of their intended destinations. Regulations governing cannabinoids, ingredients, testing, labels and product claims vary between the UK, European countries and North American jurisdictions. Beard Bros and BRITISH CANNABIS™ will apply their combined experience throughout development and market introduction.
“Beard Bros has always believed that good cannabinoid products begin with a clear purpose and honest education,” said Bill Levers, co-founder and CEO of Beard Bros. “British Cannabis brings years of manufacturing and regulatory experience in the UK. This collaboration gives us the opportunity to combine those strengths and create products designed for the people and markets they are intended to serve.”
Connecting Established Experience From Both Sides of the Atlantic
Beard Bros was founded by brothers Bill and Jeff Levers and grew from their involvement in cannabis culture, patient advocacy and legal cannabis operations. The company has operated legally in California since 2013 and established its regulated-market foundation through licensed manufacturing and distribution.
Beard Bros currently operates cannabis product programs in California and Massachusetts. The company also plans to begin operating in Maine and Connecticut before the end of the fourth quarter of 2026, extending its presence across regulated markets on both coasts.
Its product work is supported by Beard Bros Media, which was founded in 2018 as a direct extension of the company’s roots in cannabis. Through original journalism, interviews, live programming, education and commercial media services, Beard Bros Media has built a channel for communicating with patients, consumers and industry professionals.
This combination of product experience and media reach gives Beard Bros the ability to support international product introductions with education and storytelling. The company can communicate the purpose and product knowledge behind the range while helping consumers understand how cannabinoid products differ across markets.
Founded in 2015, BRITISH CANNABIS™ is a vertically integrated British cannabinoid company with capabilities spanning research, extraction, formulation, manufacturing and distribution. Through its manufacturing operations in England, the company develops and produces both its own branded ranges and bespoke products for commercial partners.
Its portfolio includes CBD by BRITISH CANNABIS™, ACCESS CBD®, BRITISH CANNABIS™ MEDICINES and SEVEN by BRITISH CANNABIS™, among other brands, with products across consumer wellness, supplements, cosmetics and prescription medical cannabis. This breadth of experience enables the company to support product development from initial formulation through to production and supply, with an understanding of the distinct requirements of consumer and medical markets.
The collaboration builds on that established infrastructure, creating opportunities to develop Beard Bros-branded products for the UK and eligible European markets while extending the international reach of British-manufactured cannabinoid products.
Beard Bros contributes brand identity, product concepts, North American market experience and an established cannabis media voice. BRITISH CANNABIS™ contributes formulation and manufacturing capabilities, an established brand portfolio and commercial experience across consumer and prescription cannabinoid markets. The collaboration creates a practical structure for applying those capabilities across international markets.
Building a CBD and CBG Product Range
CBD tinctures and gummies will form part of the planned range. Both categories are familiar to consumers and provide a clear foundation for introducing Beard Bros cannabinoid products to a wider international audience.
CBG formulations will also be included for eligible products and markets. Cannabigerol has gained attention as consumers and product developers become more familiar with cannabinoids beyond CBD. Its inclusion gives the companies an opportunity to develop differentiated formulas while expanding education surrounding minor cannabinoids.
Product availability will depend on the rules that apply to each format and destination. The companies will evaluate ingredients, cannabinoid profiles, testing requirements, packaging and claims as part of the development process for each market.
BRITISH CANNABIS™ will contribute its formulation expertise, manufacturing infrastructure and experience producing cannabinoid oils, gummies and other established product formats. Its capabilities will support the development and production of market-specific formulations, with attention to product quality, consistency and applicable regulatory requirements. Beard Bros brings product direction informed by its history with cannabinoid consumers in regulated American markets.
Transdermal Patches and Vapes Planned for the Future
The companies may expand the range with transdermal patches and cannabinoid vapes in the future, subject to product development and the rules governing each market.
Transdermal patches offer a distinct delivery format for wellness consumers seeking an alternative to ingestible products. They align with the broader goal of creating approachable products that can fit into established daily routines.
Cannabinoid vapes provide another potential category for future development. Formulations and market availability will be determined by the regulations governing vape products, cannabinoid ingredients, packaging and sales in each jurisdiction.
Bringing International Products to North America
The collaboration is designed to create product opportunities in both directions. Beard Bros will work with BRITISH CANNABIS™ to bring Beard Bros-branded formulations to the UK and eligible European markets while evaluating British-manufactured cannabinoid products for North American distribution.
Beard Bros’ current cannabis product operations in California and Massachusetts, followed by its planned Maine and Connecticut expansion, provide a growing American foundation for that work. Its industry relationships and media reach can also support direct-to-consumer, wholesale and compliant distribution opportunities for federally lawful cannabinoid products.
North American expansion requires attention to federal law and individual state requirements. Formulation, testing, labeling, marketing and distribution will be reviewed according to the destination market.
The incoming federal hemp restrictions add another consideration. Any products developed for the US market will be formulated, tested, labelled and marketed in accordance with the applicable federal and state requirements in force at the time. If those restrictions take effect as scheduled, products developed by Beard Bros and BRITISH CANNABIS™ for the American market will be formulated, tested, labeled and marketed to comply with the new federal requirements.
This compliance commitment supports durable product development as federal and state policies continue changing. Beard Bros has covered the federal restrictions extensively through its media platform, giving the company direct familiarity with the questions facing manufacturers, retailers and consumers.
Supporting Products With Education
Consumer education will be a central part of the international work. CBD may be widely recognized, but familiarity does not always translate into a clear understanding of strength, formulation, ingredients or product use. CBG and other developing cannabinoid categories require further explanation.
Beard Bros Media gives the collaboration an established platform for that communication. Product introductions can be supported through articles, video, interviews, social media and direct consumer education. This allows the companies to explain why a product was developed, what distinguishes its formulation and which market it was designed to serve.
The educational work can also address differences between cannabis markets. Consumers in California, Massachusetts, London or Berlin do not encounter identical products, regulations or retail systems. Market-specific communication will help international product introductions remain relevant to local audiences.
Accurate education builds trust. Beard Bros and BRITISH CANNABIS™ will support their products with specific information, responsible language and transparent positioning.
Future Medical Product Development
The commercial collaboration may also support future work involving medical cannabis and prescription cannabinoid products in the United Kingdom and Europe, although no specific medical products or launch plans have been announced.
Beard Bros brings experience with cannabis oils, tinctures and cannabinoid formulations developed around specific wellness needs.
Through BRITISH CANNABIS™ MEDICINES, BRITISH CANNABIS™ has experience developing and supplying prescription cannabinoid products for the UK medical cannabis market. This experience may inform the evaluation of future medical opportunities, subject to the appropriate clinical, manufacturing and regulatory requirements.
Cannabis-based products for medicinal use in the UK operate under controlled prescription and licensing requirements. Any future medical product development would need to proceed through the appropriate clinical, manufacturing and regulatory pathways.
Expanding the Beard Bros International Presence
The BRITISH CANNABIS™ collaboration represents another step in Beard Bros’ continued growth beyond its California roots.
Beard Bros currently operates cannabis product programs in California and Massachusetts and expects Maine and Connecticut to follow before the end of the fourth quarter of 2026. Its work with BRITISH CANNABIS™ extends that growth internationally through UK manufacturing, product development and market knowledge.
For BRITISH CANNABIS™, the collaboration supports its international growth ambitions, creating an opportunity to introduce its British-manufactured products to new audiences and develop commercial relationships in North America. It also builds on the company’s role as a formulation and manufacturing partner for brands seeking to enter or expand within the UK and eligible European cannabinoid markets.
“BRITISH CANNABIS™ has spent more than a decade building expertise across cannabinoid research, formulation and manufacturing, with products spanning consumer wellness and prescription medicines,” said Adam Windish, CEO of BRITISH CANNABIS™. “This collaboration allows us to build on that foundation, developing Beard Bros products for the UK and eligible European markets while opening new opportunities for our British-manufactured range in North America. We see significant potential to combine our capabilities and bring high-quality, market-specific products to a wider international audience.”
The companies will continue developing the product range and identifying appropriate sales and distribution channels. CBD tinctures, CBD gummies and eligible CBG formulations establish the opening direction, with transdermal patches and cannabinoid vapes subject to future development and regulatory review.
The commercial collaboration gives Beard Bros and BRITISH CANNABIS™ a foundation for creating compliant cannabinoid products, supporting them with credible education and introducing them across multiple regulated markets.
About Beard Bros
Founded by brothers Bill and Jeff Levers, Beard Bros is a men’s wellness, cannabis product and media organization rooted in more than a decade of legal cannabis operations and advocacy. Beard Bros currently operates cannabis product programs in California and Massachusetts, with Maine and Connecticut planned before the end of the fourth quarter of 2026. Beard Bros Pharms develops cannabis and cannabinoid wellness products, while Beard Bros Media provides original journalism, education, brand storytelling and strategic marketing for the cannabis community.
Learn more at BeardBrosPharms.com.
About BRITISH CANNABIS™
Founded in 2015, BRITISH CANNABIS™ is a British cannabinoid company specializing in research, extraction, formulation, manufacturing and distribution. With manufacturing operations in England, the company develops its own branded products and provides bespoke formulation, white-label manufacturing and supply services to commercial partners.
Its portfolio includes CBD by BRITISH CANNABIS™, ACCESS CBD®, BRITISH CANNABIS™ MEDICINES and SEVEN by BRITISH CANNABIS™, among other brands, spanning supplements, wellness, cosmetics and prescription medical cannabis.
Learn more at BritishCannabis.org.
